Differential effect of Shenmai injection, a herbal preparation, on the cytochrome P450 3A-mediated 1′-hydroxylation and 4-hydroxylation of midazolam

Chemico-Biological Interactions

Volumn 180, Issue 3, 2009, Pages 440-448

  Xia, Chunhua ^a,b   Sun, Jianguo ^a   Wang, Guangji ^a   Shang, Lili ^a   Zhang, Xiaoxuan ^a   Zhang, Rong ^a   Wang, Xiaojin ^a   Hao, Haiping ^a   Xie, Lin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

CYP3A; Interaction; Midazolam metabolism; Shenmai injection

Indexed keywords

CHINESE DRUG; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLAVONE DERIVATIVE; GINSENG EXTRACT; GINSENOSIDE; GINSENOSIDE RB 1; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; KETOCONAZOLE; LIPID; METHANOL; MIDAZOLAM; OPHIOPOGON ROOT; OPHIOPOGONIN D; OPHIOPOGONONE A; SAPONIN; SHENMAI; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; ELUTION; HERBAL MEDICINE; INHIBITION KINETICS; LIPID SOLUBILITY; LIVER MICROSOME; MALE; NONHUMAN; RAT; SOLID PHASE EXTRACTION;

ANIMALS; CYTOCHROME P-450 CYP3A; DRUG COMBINATIONS; DRUGS, CHINESE HERBAL; HUMANS; HYDROXYLATION; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; MIDAZOLAM; RATS; RECOMBINANT PROTEINS;

OPHIOPOGON; RATTUS;

EID: 67349150268     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.03.022     Document Type: Article

References (30)

1. Bailey D.C., Arnold J.M., Munoz C., and Spence J.D. Grapefruit juice-felodipine interaction: mechanism, predictability and effect of naringin. Clin. Pharmacol. Ther. 53 (1993) 637-642
2. Yee G.C., Stanley D.L., Pessa L.J., DallaCosta T., Beltz S.E., Ruiz J., and Lowenthal D.T. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 345 (1995) 955-956
3. Kupferschmidt H.H., Fattinger K.E., Ha H.R., Follath F., and Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45 (1998) 355-359
4. Kupferschmidt H.H., Ha H.R., Ziegler W.H., Meier P.J., and Krahenbuhl S.S. Interaction between grapefruit juice and MDZ in humans. Clin. Pharmacol. Ther. 58 (1995) 20-28
5. Lilja J.J., Kivisto K.T., and Neuvonen P.J. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64 (1998) 477-483
6. Iwata H., Tezuka Y., Shiratsuka A., and Watabe T. Identification and characterization of potent CYP3A4 inhibitors in schisandra fruit extract. Drug Metab. Dispos. 32 (2004) 1351-1358
7. Zhou S., Chan E., Pan S.Q., Huang M., and Lee E.J. Pharmacokinetic interactions of drugs with St. John's wort. J. Psychopharmacol. 18 (2004) 262-276
8. Janetzky K., and Morreale A.P. Probable interaction between warfarin and ginseng. Am. J. Health-Syst. Pharm. 54 (1997) 692-693
9. Donovan J.L., DeVane C.L., Chavin K.D., Taylor R.M., and Markowitz J.S. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab. Dispos. 31 (2003) 519-522
10. Jiang X., Williams K.M., Liauw W.S., Ammit A.J., Roufogalis B.D., Duke C.C., Day R.O., and McLachlan A.J. Effect of St. John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 57 (2004) 592-599
11. Yuan C.S., Wei G., Dey L., and Karrison T. American ginseng reduces warfarin's effect in healthy patients: a randomized controlled trial. Ann. Intern. Med. 141 (2004) 23-27
12. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Cui Y., and Ang C.Y. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 72 (2002) 276-287
13. Henderson G.L., Harkey M.R., Gershwin M.E., Hackman R.M., Stern J.S., and Stresser D.M. Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 65 (1999) 209-214
14. Liu Y., Ma H., Zhang J.W., Deng M.C., and Yang L. Influence of ginsenoside Rh1 and F1 on human cytochrome p450 enzymes. Planta Med. 72 (2006) 126-131
15. Liu Y., Zhang J.W., Li W., Ma H., Sun J., Deng M.C., and Yang L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol. Sci. 91 (2006) 356-364
16. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 78 (2006) 2131-2145
17. Kim H., Yoon Y.J., Shon J.H., Cha I.J., Shin J.G., and Liu K.H. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab. Dispos. 34 (2006) 521-523
18. Shou M., Mei Q., Ettore J.R., Dai R., Baillie T.A., and Rushmore T.H. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem. J. 340 (1999) 845-853
19. Lin Y., Lu P., Tang C., Mei Q., Sandig G., Rodrigues A.D., Rushmore T.H., and Shou M. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab. Dispos. 29 (2001) 368-374
20. Schrag M.L., and Wienkers L.C. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab. Dispos. 29 (2001) 70-75
21. Shou M., Dai R., Cui D., Korzekwa K.R., Baillie T.A., and Rushmore T.H. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 276 (2001) 2256-2262
22. Galetin A., Clarke S.E., and Houston J.B. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab. Dispos. 31 (2003) 1108-1116
23. Kenworthy K.E., Clarke S.E., Andrews J., and Houston J.B. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 29 (2001) 1644-1651
24. Galetin A., Clarke S.E., and Houston J.B. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 30 (2002) 1512-1522
25. Rogers J.F., Rocci M.L., Haughey D.B., and Bertino J.S. An evaluation of the suitability of intravenous MDZ as an in vivo marker for hepatic cytochrome P4503A activity. Clin. Pharmacol. Ther. 73 (2003) 153-158
26. Link B., Haschke M., Wenk M., and Krähenbühl S. Determination of MDZ and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21 (2007) 1531-1540
27. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., and Tracy T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37 (1998) 4137-4147
28. Zhang W.X., and Lim L.Y. Effects of spice constituents on p-gp-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab. Dispos. 36 (2008) 1283-1290
29. Cameron M.D., Wen B., Allen K.E., Roberts A.G., Schuman J.T., Campbell A.P., Kunze K.L., and Nelson S.D. Cooperative binding of midazolam with testosterone and alphanaphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry 44 (2005) 14143-14151
30. Torimoto N., Ishii I., Hata M., Nakamura H., Imada H., Ariyoshi N., Ohmori S., Igarashi T., and Kitada M. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 42 (2003) 15068-15077